http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : Shrawani Lamichhane (검색결과 4 건)
- 무료
- 기관 내 무료
- 유료
-
Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy
Shrawani Lamichhane,이상길 대한약학회 2020 Archives of Pharmacal Research Vol.43 No.1
Albumin is a biocompatible, non-immunogenicand versatile drug carrier system. It has been widely usedto extend the half-life, enhance stability, provide protectionfrom degradation and allow specifi c targeting of therapeuticagents to various disease states. Understanding the roleof albumin as a drug delivery and distribution system hasincreased remarkably in the recent years from the developmentof albumin-binding prodrugs to albumin as a drugcarrier system. The extraordinary surface property of albuminmakes it possible to bind various endogenous and exogenousmolecules. This review succinctly deals with severalalbumin-drug conjugates and nanoparticles along with theirpreparation techniques and focuses on surface-modifi edalbumin and targeting of albumin formulation to specifi corgans and tissues. It also summarizes research eff orts onalbumin nanoparticles used for delivering drugs to tumorcells and describes their role in permeation through tumorvasculature and in receptor mediated endocytosis, which isalso described in this review. The versatility of albumin andease of preparation makes it a suitable drug carrier system,swhich is the major objective of this review.
-
Shrawani Lamichhane,Jo-Eun Seo,Taekwang Keum,Gyubin Noh,Santosh Bashyal,Seong-Wan Cho,Eun-Hee Lee,Sangkil Lee 대한약학회 2022 Archives of Pharmacal Research Vol.45 No.1
Improving the aqueous solubility of poorlysoluble compounds have been a major issue in the pharmaceuticalindustry. In the present study, binary amorphoussolid dispersions (SDs) of Coenzyme Q10 (CoQ 10 ), a biopharmaceuticsclassifi cation system (BCS) II compound andSoluplus ® were prepared to enhance the solubility and pharmacokineticproperties compared to crystalline CoQ 10 . SDswere prepared with diff erent ratios of CoQ 10 and Soluplus ®(1:3, 1:5, and 1:7) using spray drying technology, and thephysicochemical properties of the SDs were evaluated. X-raypowder diff raction, diff erential scanning calorimetry, andscanning electron microscopy suggested the conversion ofthe crystalline form of CoQ 10 to a binary amorphous systemin the SDs. Fourier transform infrared spectroscopy revealedno potential interactions between CoQ 10 and Soluplus ® . The solubility of the optimal SD formulation (SD 1:7)was approximately 9000-fold higher than that of crystallineCoQ 10, and the increment was Soluplus ® concentrationdependent. As a result, optimized SD 1:7 also showed significantly enhanced dissolution rate where maximum drugrelease was observed within 30 min in two diff erent dissolutionmedia. Moreover, in contrast to crystalline CoQ 10, CoQ 10 SDs showed improved pharmacokinetic parameters. Thus, the SD 1:7 formulation is expected to improve biopharmaceuticalproperties and therapeutic effi cacy of CoQ 10 .
-
노규빈,금태광,Bashyal Santosh,Seo Jo-Eun,Shrawani Lamichhane,Kim Jeong Hwan,이상길 한국약제학회 2022 Journal of Pharmaceutical Investigation Vol.52 No.1
Background The biopharmaceuticals market has grown rapidly in recent years owing to the low toxicity and high therapeutic efficacy of peptide and protein drugs. However, due to their low stability, biopharmaceuticals have to be administrated via invasive routes, and there is an unmet need for alternative routes. The most familiar and preferred alternative route of administration is the oral route; however, peptide and protein drugs are readily affected by the harsh gastrointestinal environment, resulting in low oral bioavailability. Lipid-based drug delivery systems (LDDSs) for oral administration protect the incorporated drugs and enhance their absorption in the GI tract. However, only lipophilic substances can be stably incorporated in LDDSs, and hydrophilic peptides and proteins require lipidation via, e.g., hydrophobic ion pairing (HIP). Area covered This review discusses the issues that hamper the oral administration of peptides and proteins and introduces HIP and LDDSs as strategies to overcome these. The principle of HIP complexation, the parameters to be considered for complexation, and the various counterions used are described. As for LDDSs, the advantages of self-emulsifying drug delivery systems (SEDDSs), which are suitable for oral peptide and protein delivery, and in vivo study results are described. Expert opinion HIP complexes are prepared based on an understanding of the characteristics of drugs and counterions. HIP complexes of peptides and proteins in the oil phase of SEDDSs are protected from the GI environment and therefore, improved absorption is expected. Although their fundamental mechanisms remain unclear and require further study, HIPincorporated SEDDSs provide a potential strategy for oral peptide and protein delivery.
-
Kanchan Shakhakarmi,Jo-Eun Seo,Shrawani Lamichhane,Chhitij Thapa,Sangkil Lee 대한약학회 2023 Archives of Pharmacal Research Vol.46 No.4
Epidermal growth factor (EGF) has been used in wound management and regenerative medicine since the late 1980s. It has been widely utilized for a long time and still is because of its excellent tolerability and efficacy. EGF has many applications in tissue engineering, cancer therapy, lung diseases, gastric ulcers, and wound healing. Nevertheless, its in vivo and during storage stability is a primary concern. This review focuses on the topical use of EGF, especially in chronic wound healing, the emerging use of biomaterials to deliver it, and future research possibilities. To successfully deliver EGF to wounds, a delivery system that is proteolytically resistant and stable over the long term is required. Biomaterials are an area of interest for the development of such systems. These systems may be used in non-healing wounds such as diabetic foot ulcers, pressure ulcers, and burns. In these pathologies, EGF can reduce the risk of amputation of the lower extremities, as it accelerates the wound healing process. Furthermore, appropriate delivery system would also stabilize and control the EGF release profile in a wound. Several in vitro and in vivo studies have already proven the efficacy of such systems in the above-mentioned types of wounds. Moreover, several formulations such as ointments and intralesional injections are already available on the market. However, these products are still problematic in terms of inadequate diffusion of EGF, low bioavailability storage conditions, and shelf-life. This review discusses the nano formulations comprising biomaterials infused with EGF which could be a promising delivery system for chronic wound healing in the future.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
